真实生物赴港IPO，多管线创新药布局凸显战略雄心

Core Viewpoint - Real Bio Technology Co., Ltd. has submitted a main board listing application to the Hong Kong Stock Exchange, showcasing its innovative research-driven approach in the fields of viral infections, tumors, and cardiovascular diseases, with significant development potential and strategic depth [1] Group 1: Product Pipeline and Development - The core product Azvudine has received conditional approval for treating HIV in July 2021 and COVID-19 in July 2022, marking it as the first oral antiviral drug developed by a Chinese company for COVID-19 [2] - Other key products include CL-197, a long-acting HIV treatment candidate currently in Phase II clinical trials, and Doxitinib, a third-generation EGFR-TKI targeting unmet needs in advanced non-small cell lung cancer, with Phase I results showing efficacy similar to Osimertinib but better safety [2][3] - Azvudine also holds significant potential in oncology, being the only nucleoside drug with dual mechanisms to inhibit tumor cell DNA synthesis and enhance immune response [2] Group 2: Research and Development Capabilities - The company is expanding its oncology applications, developing both monotherapy and combination therapies for multiple cancers, with IND approval for Azvudine/Doxitinib in non-small cell lung cancer expected by September 2025 [3] - Real Bio has established a comprehensive R&D system, including platforms for high-selectivity nucleoside anti-tumor drug development and drug target discovery, ensuring systematic support for continuous innovation [4] - The company has regained exclusive commercialization rights for Azvudine from Fosun Pharma, indicating the drug's potential value and expansion opportunities [4] Group 3: Commercialization and Market Position - Azvudine's successful commercialization is evidenced by its inclusion in the National Reimbursement Drug List (NRDL) in 2023, with over 10 million bottles sold and coverage across more than 50,000 medical terminals [5] - The company has established a GMP-certified production base with an annual capacity of approximately 3 billion tablets, supporting current and future product supply [5] - Real Bio's pipeline strategically targets high-prevalence disease areas, with a focus on unmet clinical needs in HIV and oncology, providing a unique clinical differentiation advantage [6]